Profile data is unavailable for this security.
About the company
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider. The Company is principally engaged in generic finished dosage forms (FDF), Oncology formulations and research and development services to cater to the needs of the global pharmaceutical industry. The Company’s focus areas include antibiotics, hypertension, general pain management, cardiovascular, diabetics and oncology formulations. In cardiology, the Company is delivering effective treatments for heart-related conditions. Its CNS products address neurological disorders, while its diabetology solutions focus on advanced diabetes management. It also contributes to the global fight against malaria with its anti-malarial medications. Additionally, the Company offers essential vitamins, antibiotics for bacterial infections, and comprehensive pain management solutions. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, and others.
- Revenue in INR (TTM)1.63bn
- Net income in INR76.61m
- Incorporated1993
- Employees378.00
- LocationMedicamen Biotech Ltd1506, Chiranjiv Tower, 43, Nehru PlaceNEW DELHI 110019IndiaIND
- Phone+91 1 147589500
- Fax+91 1 126213081
- Websitehttps://medicamen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyka Labs Ltd | 1.38bn | 80.16m | 4.08bn | 423.00 | 51.54 | 3.94 | 27.77 | 2.95 | 2.22 | 2.22 | 38.36 | 29.01 | 0.8317 | 5.05 | 3.95 | -- | 4.76 | 2.35 | 6.38 | 3.44 | 59.86 | 62.49 | 5.73 | 3.29 | 1.18 | 4.91 | 0.2745 | -- | 24.55 | 17.63 | 421.84 | -- | 70.13 | -- |
| Brooks Laboratories Ltd | 1.00bn | -124.00m | 4.21bn | 293.00 | -- | 4.30 | -- | 4.19 | -4.72 | -4.72 | 38.06 | 33.30 | 0.9385 | 7.06 | 5.54 | -- | -11.59 | -14.21 | -14.75 | -23.39 | 33.94 | 26.76 | -12.35 | -25.22 | 1.08 | 0.1945 | 0.0718 | -- | 3.86 | 3.45 | 49.13 | -- | -6.37 | -- |
| Albert David Ltd | 3.46bn | 172.01m | 5.11bn | 1.50k | 29.70 | 1.30 | 21.14 | 1.48 | 30.14 | 30.14 | 605.91 | 687.70 | 0.6851 | 2.12 | 11.83 | -- | 3.41 | 8.95 | 4.27 | 11.63 | 66.37 | 60.78 | 4.97 | 11.56 | 2.79 | -9.61 | 0.0304 | 12.41 | -4.61 | 1.51 | -77.19 | -2.14 | -0.7463 | -6.51 |
| Nectar Lifesciences Ltd | 16.82bn | 170.01m | 5.11bn | 1.69k | 30.12 | -- | 6.53 | 0.3038 | 0.7566 | 0.7566 | 73.81 | -- | -- | -- | -- | 9,977,625.00 | -- | -0.2956 | -- | -0.541 | 30.25 | 16.49 | 1.01 | -0.4053 | -- | 1.40 | -- | -- | 10.53 | -9.56 | 120.66 | -36.29 | -5.06 | -- |
| ZIM Laboratories Ltd | 3.79bn | 121.65m | 5.41bn | 577.00 | 44.38 | 2.14 | 16.75 | 1.43 | 2.50 | 2.50 | 77.51 | 51.77 | 0.825 | 2.00 | 3.66 | 6,568,995.00 | 2.65 | 4.08 | 4.10 | 6.64 | 55.72 | 48.54 | 3.21 | 4.24 | 0.8706 | 2.07 | 0.3183 | 0.00 | 3.16 | 6.42 | -29.46 | 29.84 | 17.10 | -- |
| Medicamen Biotech Ltd | 1.63bn | 76.61m | 5.46bn | 378.00 | 62.97 | 2.39 | 40.09 | 3.36 | 6.39 | 6.39 | 133.36 | 168.19 | 0.5497 | 1.39 | 2.62 | -- | 2.22 | 4.69 | 3.06 | 6.63 | 47.94 | 40.46 | 4.03 | 8.13 | 1.31 | 2.15 | 0.1352 | 10.41 | -9.35 | 5.31 | -34.97 | -11.77 | -36.30 | 14.87 |
| Venus Remedies Ltd | 6.48bn | 453.30m | 6.17bn | 1.19k | 13.60 | 1.10 | 9.09 | 0.9516 | 33.92 | 33.92 | 485.82 | 419.65 | 0.9652 | 3.41 | 6.72 | -- | 6.75 | 6.67 | 8.05 | 8.08 | 41.56 | 38.36 | 7.00 | 6.87 | 2.58 | 683.83 | 0.003 | -- | 7.72 | 13.81 | 59.07 | -- | 18.63 | -- |
| Accent Microcell Ltd | 2.65bn | 330.63m | 6.68bn | 174.00 | 18.72 | 3.18 | 17.91 | 2.52 | 14.87 | 14.87 | 118.99 | 87.56 | 1.22 | 4.78 | 4.46 | -- | 15.26 | -- | 18.12 | -- | 38.92 | -- | 12.50 | -- | 3.97 | 109.07 | 0.0077 | -- | 7.77 | -- | 9.60 | -- | -- | -- |
| IND Swift Laboratories Ltd | 4.47bn | 3.54bn | 6.79bn | 47.00 | 1.87 | -- | 1.85 | 1.52 | 59.95 | 59.95 | 75.95 | -- | -- | -- | -- | 95,132,490.00 | -- | 5.00 | -- | 6.13 | 46.06 | 41.12 | 79.19 | 8.52 | -- | -- | -- | 0.00 | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Kilitch Drugs (India) Ltd | 1.98bn | 263.18m | 7.14bn | 168.00 | 27.13 | 3.53 | 25.81 | 3.60 | 16.37 | 16.37 | 123.25 | 125.81 | 0.7175 | 12.91 | 2.68 | -- | 8.88 | 5.16 | 12.07 | 7.38 | 37.21 | 36.10 | 12.38 | 8.41 | 1.88 | 5.55 | 0.1978 | -- | 28.47 | 30.05 | 82.86 | 99.64 | 34.88 | -- |
